HC Wainwright & Co. : The TransCode Therapeutics (RNAZ.US) rating was reaffirmed, adjusted from buy to buy rating, and the target price was adjusted from $3.00 to $3.00.
HC Wainwright & Co.：重申TransCode Therapeutics(RNAZ.US)评级，由买入调整至买入评级, 目标价由3.00美元调整至3.00美元。
HC Wainwright & Co. : The TransCode Therapeutics (RNAZ.US) rating was reaffirmed, adjusted from buy to buy rating, and the target price was adjusted from $3.00 to $3.00.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.